Trial · NCT02729194

Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma

NCT02729194, Early phase 1, Completed, University of Michigan Rogel Cancer Center; results first posted 2019-06-10

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma. Trials, record NCT02729194. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02729194

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
NCT number: NCT02729194
Status: Completed
Phases: Early phase 1
Enrollment: 16 participants, actual
Lead sponsor: University of Michigan Rogel Cancer Center
Conditions: Carcinoma, Renal Cell
Interventions: Pazopanib, Low Fat Diet
First posted: 2016-04-06
Last updated: 2019-06-10
Results first posted: 2019-06-10

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Grade 3 or 4 Adverse Events	Through 12 weeks of treatment to 30 days post-treatment	Number of grade 3 or 4 adverse events associated with pazopanib administered with a low fat meal by CTCAE version 4.0.
Primary	Number of Participants With Dose Reductions	12 weeks
Primary	Duration of Treatment	12 weeks	The median duration of treatment will be reported.
Primary	Median Total Dose	12 weeks	Median total dose given.
Secondary	Percentage of Patients That Respond to Treatment (Overall Response) With Pazopanib Administered Along With a Low Fat Diet	12 Weeks after start of study treatment	To estimate the overall response proportion to pazopanib administered with a low fat meal by RECIST 1.1 criteria. Overall response is defined as the number patients that experience Partial Response (PR) or Complete Response (CR). CR is defined as the disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions. PR is defined as At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions.
Secondary	Number of Participants With Complete Response	12 Weeks after start of study treatment	Complete response is defined as the disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions.
Secondary	Number of Patients With Partial Response	12 Weeks after start of study treatment	Partial response is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions.

Source ClinicalTrials.gov

Outcomes7

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Grade 3 or 4 Adverse Events	Through 12 weeks of treatment to 30 days post-treatment	16 participants were enrolled and treated.	adverse events	NUMBER
PRIMARY	Number of Participants With Dose Reductions	12 weeks	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Duration of Treatment	12 weeks	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	weeks	MEDIAN
PRIMARY	Median Total Dose	12 weeks	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	mg	MEDIAN
SECONDARY	Percentage of Patients That Respond to Treatment (Overall Response) With Pazopanib Administered Along With a Low Fat Diet	12 Weeks after start of study treatment	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	percentage of participants	NUMBER
SECONDARY	Number of Participants With Complete Response	12 Weeks after start of study treatment	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Patients With Partial Response	12 Weeks after start of study treatment	16 participants were enrolled. 13 of the 16 enrolled participants completed the 12 weeks of pazopanib therapy on study protocol.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Grade 3 or 4 Adverse Events	Pazopanib	Grade 3 adverse events associated with treatment	5		adverse events
Number of Grade 3 or 4 Adverse Events	Pazopanib	Grade 4 adverse events associated with treatment	0		adverse events
Number of Participants With Dose Reductions	Pazopanib		3		Participants
Duration of Treatment	Pazopanib		12	Full Range 1 to 12	weeks
Median Total Dose	Pazopanib		42,700	Full Range 1200 to 63,200	mg
Percentage of Patients That Respond to Treatment (Overall Response) With Pazopanib Administered Along With a Low Fat Diet	Pazopanib		38.46	95% Confidence Interval 11 to 59	percentage of participants
Number of Participants With Complete Response	Pazopanib		0		Participants
Number of Patients With Partial Response	Pazopanib		5		Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Pazopanib	16
Overall Study	COMPLETED	Pazopanib	13
Overall Study	NOT COMPLETED	Pazopanib	3

Source ClinicalTrials.gov

Adverse events54

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Pazopanib	1	16	1
other	Chest pain - cardiac	Cardiac disorders	Pazopanib	1	16	1
other	Sick sinus syndrome	Cardiac disorders	Pazopanib	1	16	1
other	Middle ear inflammation	Ear and labyrinth disorders	Pazopanib	1	16	1
other	Endocrine disorders - Other	Endocrine disorders	Pazopanib	1	16	1
other	Hyperthyroidism	Endocrine disorders	Pazopanib	2	16	2
other	Hypothyroidism	Endocrine disorders	Pazopanib	1	16	1
other	Blurred vision	Eye disorders	Pazopanib	1	16	1
other	Abdominal pain	Gastrointestinal disorders	Pazopanib	2	16	2
other	Constipation	Gastrointestinal disorders	Pazopanib	2	16	2

1 to 10 of 54Source ClinicalTrials.gov

See all 54 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Pazopanib	0	16
Total, other adverse events	Pazopanib	15	16
Total, serious adverse events	Pazopanib	1	16

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30393825	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02729194

GET https://conductscience.org/api/trials/v1/NCT02729194/events?page=2

API reference For AI assistants